Luis García-Fuentes

Prof. Dr. Luis García-Fuentes

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2009 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
JCJuan M. Casas-Solvas
Juan M. Casas-Solvas
EOEmilia Ortiz‐Salmerón
Emilia Ortiz‐Salmerón
Ignacio FernándezIgnacio Fernández
Ignacio Fernández
LGLuis García-Fuentes
Luis García-Fuentes
FSFrancisco Santoyo-Gonzalez
Francisco Santoyo-Gonzalez
AVAntonio Vargas-Berenguel
Antonio Vargas-Berenguel

19 December 2013 in Langmuir
Verified
Journal Article
Closed access
AAAhmet Aykaç
Ahmet Aykaç
MMManuel C. Martos-Maldonado
Manuel C. Martos-Maldonado
JCJuan M. Casas-Solvas
Juan M. Casas-Solvas
IQIndalecio Quesada-Soriano
Indalecio Quesada-Soriano
FGFederico García-Maroto
Federico García-Maroto
AVAntonio Vargas-Berenguel
Antonio Vargas-Berenguel

29 December 2008 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
JCJuan M. Casas-Solvas
Juan M. Casas-Solvas
EOEmilia Ortiz‐Salmerón
Emilia Ortiz‐Salmerón
JGJuan J. Giménez‐Martínez
Juan J. Giménez‐Martínez
LGLuis García-Fuentes
Luis García-Fuentes
LCLuis Fermin Capitan-Vallvey
Luis Fermin Capitan-Vallvey
AVAntonio Vargas-Berenguel
Antonio Vargas-Berenguel

1 January 2014 in Food Control
Verified
Journal Article
Closed access
AAAna Aguilera
Ana Aguilera
AVAntonio Valverde
Antonio Valverde
FCFrancisco Camacho
Francisco Camacho
MBMourad Boulaid
Mourad Boulaid
LGLuis García-Fuentes
Luis García-Fuentes

1 June 2012 in Food Control
Verified
Journal Article
Closed access
AAAna Aguilera
Ana Aguilera
AVAntonio Valverde
Antonio Valverde
FCFrancisco Camacho
Francisco Camacho
MBMourad Boulaid
Mourad Boulaid
LGLuis García-Fuentes
Luis García-Fuentes

1 July 2013 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
RTR. Tellez-Sanz
R. Tellez-Sanz
LGLuis García-Fuentes
Luis García-Fuentes
AVAntonio Vargas-Berenguel
Antonio Vargas-Berenguel
Over the last decade an increasing number of studies have been published reporting on the inhibitory potency or selectivity that several types of ligands show against human galectin-3 (hGal-3). The reason for this interest lies in the many important roles galectins play both in intra and extra-cellular functions. Among galectins, galectin-3 stands out because it is the only known member of its subfamily in mammals, is small and monomeric but capable of aggregating, and is known to be involved in a large number of disease processes, from cancer to heart failure. These characteristics and roles make hGal-3 an ideal target for drugs. Since it binds β-galactosides, like the rest of the galectin family of proteins, the search and design of potent and at the same time selective inhibitors for it is not an easy task. Herein we discuss the chemical features of the most potent inhibitors described so far, as well as the structural basis of their exhibited selectivity, in order to shed light on the rational design of drugs against this target.